IMV Inc. has developed a delivery platform called DPX that attracts immune cells to the injection site, enabling the immune system to generate a robust and sustained response against cancer. Their lead drug candidate, Maveropepimut-S (DPX-Survivac), has shown positive results in clinical trials for ovarian cancer and Diffuse Large B Cell Lymphoma. IMV Inc. collaborates with pharmaceutical companies, government agencies, and academic institutions for research and development purposes.